Many psychiatric pharmacists are not familiar with integrated models for hepatitis C virus (HCV) screening and treatment due to a lack of publications and education in this area. However, collaborative care models with clinical pharmacist integration have demonstrated improved patient outcomes. Integrating psychiatric pharmacists into the screening and treatment of HCV improves holistic patient care, reduces the burden on other providers, and increases screening and treatment rates. Given the high rates of mental illness and substance use disorders among patients with HCV, educating psychiatric pharmacists on HCV care is essential to address the increasing rates of HCV infection in these vulnerable populations. This session aims to help psychiatric pharmacists learn about screening and treating HCV using integrated care models, ultimately benefiting underserved patient populations.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Course Requirements
To receive ACPE credit for this session, you must:
- Register for this course.
- Review the full content of the activity and reflect upon its teachings.
- Complete the evaluation at the end of the activity.
- Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Faculty Information
View biographical information
Ben Miskle, PharmD
Clinical Assistant Professor, University of Iowa Carver College of Medicine, University of Iowa College of Pharmacy
Ben Miskle is a Clinical Pharmacy Specialist at University of Iowa Health Care, and a Clinical Assistant Professor at the University of Iowa Carver College of Medicine and University of Iowa College of Pharmacy. Prior to arriving in Iowa, he completed a psychiatric pharmacy residency program at the Chillicothe Veterans Affairs Medical Center, in Chillicothe, Ohio. He has published articles on addiction treatment services across the United States, substance use and stigma in pregnancy, older adult first-time admissions for substance use disorders, and cannabis use disorder treatment to name a few. Dr. Miskle has received multiple grants from the Department of Health and Human Services (HHS) and the Substance Abuse and Mental Health Services Administration (SAMHSA). He runs the integrated access (i-ACCESS) project, for people needing testing and treatment for hepatitis C and HIV while enrolled in substance use disorder treatment across Iowa. He started the Naloxone in Schools (IA-NEXT) project, to assist schools across the state of Iowa on overdose and naloxone education. He is also co-director of The Substance Use Disorder Training Expansion to Advance Multidisciplinary Services in Iowa (SUD-TEAMS-Iowa) project, implementing an evidence-based substance use disorder curriculum in multiple healthcare specialty training programs across Iowa.
Learning Objectives
- Provide rationale for integrating hepatitis C virus (HCV) care into a psychiatric pharmacy practice.
- Describe the role of the psychiatric pharmacist in an integrated care model for enhancing HCV screening and treatment.
- Recommend an HCV screening and/or monitoring plan for patients receiving psychiatric medication management.
Continuing Education Credit and Disclosures
Activity Dates: 10/02/2025 - 10/02/2028
ACPE Contact Hours: 1.25
ACPE Number: 0284-0000-25-028-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View disclaimer and disclosure of off-label use
Off-Label Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA (see faculty information). The opinions expressed in the educational activity do not necessarily represent the views of AAPP and any educational partners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
View fair balance and integrity statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.